AVIR

Atea Pharmaceuticals, Inc.

Price Chart

Latest Quote

$4.40

+0.14 (+3.29%)

Current Price

Previous Close	$4.26
Open	$4.27
Day High	$4.42
Day Low	$4.27
Volume	80,863

Fetched: 2026-06-17T16:27:07

Stock Information

Shares Outstanding	80.03M
Total Debt	$634K
Cash Equivalents	$256.01M
Net Income	$-169.52M
Sector	Healthcare
Industry	Biotechnology
Market Cap	$352.12M
EPS (TTM)	$-2.11
Exchange	NMS

🌐 Visit Website

📊 Comprehensive Analysis

Company Data

Enterprise Value	$85.54M
Income	$-169.52M
Book/sh	$2.92
Cash/sh	$3.20
Employees	55

Financial Ratios

Quick Ratio	7.67
Current Ratio	7.89
Debt/Eq	0.27

Returns & Margins

ROA	-33.52%
ROE	-52.58%

Ownership

Insider Ownership	13.40%
Institutional Ownership	80.08%
Insider & Institutional transactions data not available

Valuation Ratios

Forward P/E	-3.18
P/B	1.51

Analyst Data

Recommendation	none
Target Price	$8.67

Technical Indicators

SMA20	$4.39
SMA50	$4.99
SMA200	$4.10
RSI	39.49
ATR	0.2088

Shares Float	60.23M
Short Float	12.13%
Short Ratio	21.50
Volatility	0.32
Rel Volume	0.30

Performance History

Week	+0.23%
Month	+6.28%
Quarter	-25.55%
6 Months	+39.68%
YTD	+26.44%
Year	+37.93%
3 Years	+6.28%
5 Years	-82.46%
10 Years	-85.50%

Stock Score: ⭐ Premium

Based on debt, profitability, growth, and cash flow metrics

⭐ Premium Feature

Recent Price History

Date	Close	Volume
2026-06-17	$4.40	80,863
2026-06-16	$4.26	287,700
2026-06-15	$4.35	210,700
2026-06-12	$4.49	197,800
2026-06-11	$4.36	175,500
2026-06-10	$4.39	237,400
2026-06-09	$4.36	233,300
2026-06-08	$4.32	245,300
2026-06-05	$4.25	217,600
2026-06-04	$4.42	190,300
2026-06-03	$4.21	330,200
2026-06-02	$4.27	312,500
2026-06-01	$4.38	366,200
2026-05-29	$4.67	318,800
2026-05-28	$4.73	279,000
2026-05-27	$4.55	325,200
2026-05-26	$4.53	323,200
2026-05-22	$4.42	356,200
2026-05-21	$4.24	411,700
2026-05-20	$4.19	211,600
2026-05-19	$4.15	250,600
2026-05-18	$4.14	376,000

About Atea Pharmaceuticals, Inc.

Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes oral antiviral therapeutics for patients with serious viral infections. Its lead product candidate is the regimen of bemnifosbuvir, a nucleotide NS5B inhibitor, and ruzasvir, an NS5A inhibitor, which is in Phase 3 clinical trial for the treatment of hepatitis C virus (HCV). The company also developing AT-587, that is in Phase 1 clinical trial for the treatment of chronic HEV infection. In addition, it offers a proprietary platform of nucleosides and nucleotides for virology, medicinal chemistry, and antiviral drug development. The company has a license agreement with MSD International GmbH for the development, manufacture, and commercialization of ruzasvir. Atea Pharmaceuticals, Inc. was incorporated in 2012 and is headquartered in Boston, Massachusetts.

📰 Latest News

Are Medical Stocks Lagging Atea Pharmaceuticals (AVIR) This Year?

Zacks • 2026-06-09T13:40:03Z

Spotlight On Atea Pharmaceuticals And 2 Other Prominent Penny Stocks

Simply Wall St. • 2026-05-25T12:05:26Z

Here's Why We're Watching Atea Pharmaceuticals' (NASDAQ:AVIR) Cash Burn Situation

Simply Wall St. • 2026-05-19T12:46:08Z

Down 25% in 4 Weeks, Here's Why Atea Pharmaceuticals (AVIR) Looks Ripe for a Turnaround

Zacks • 2026-05-15T13:35:02Z

Atea Pharmaceuticals, Inc. Q1 2026 Earnings Call Summary

Moby • 2026-05-13T12:30:00Z

Atea Pharmaceuticals Inc (AVIR) Q1 2026 Earnings Call Highlights: Strategic Advancements and ...

GuruFocus.com • 2026-05-13T05:01:38Z

Atea Pharmaceuticals Q1 Earnings Call Highlights

MarketBeat • 2026-05-12T22:08:10Z

Atea Pharmaceuticals, Inc. Q4 2025 Earnings Call Summary

Moby • 2026-03-06T13:30:00Z

Atea Pharmaceuticals Inc (AVIR) Q4 2025 Earnings Call Highlights: Advancing HCV Treatments and ...

GuruFocus.com • 2026-03-06T05:02:31Z

Atea Pharmaceuticals Q4 Earnings Call Highlights

MarketBeat • 2026-03-05T23:47:44Z

Period:

Income Statement (Annual)

Metric	2025-12-31	2024-12-31	2023-12-31	2022-12-31
Revenue
Total Revenue	$0	$0	$0	$0
Operating Revenue	$0	$0	$0	$0
Expenses
Total Expenses	$180,887,000	$192,950,000	$164,162,000	$130,650,000
Net Non Operating Interest Income Expense	$16,376,000	$25,490,000	$29,224,000	$11,151,000
Operating Expense	$180,887,000	$192,950,000	$164,162,000	$130,650,000
General And Administrative Expense	$32,863,000	$48,849,000	$49,919,000	$48,714,000
Income & Earnings
Net Income From Continuing Operation Net Minority Interest	$-158,349,000	$-168,385,000	$-135,956,000	$-115,909,000
Net Interest Income	$16,376,000	$25,490,000	$29,224,000	$11,151,000
Interest Income	$16,376,000	$25,490,000	$29,224,000	$11,151,000
Normalized Income	$-158,349,000	$-168,385,000	$-135,956,000	$-115,909,000
Net Income From Continuing And Discontinued Operation	$-158,349,000	$-168,385,000	$-135,956,000	$-115,909,000
Total Operating Income As Reported	$-180,887,000	$-192,950,000	$-164,162,000	$-130,650,000
Net Income Common Stockholders	$-158,349,000	$-168,385,000	$-135,956,000	$-115,909,000
Net Income	$-158,349,000	$-168,385,000	$-135,956,000	$-115,909,000
Net Income Including Noncontrolling Interests	$-158,349,000	$-168,385,000	$-135,956,000	$-115,909,000
Net Income Continuous Operations	$-158,349,000	$-168,385,000	$-135,956,000	$-115,909,000
Pretax Income	$-164,511,000	$-167,460,000	$-134,938,000	$-119,499,000
Interest Income Non Operating	$16,376,000	$25,490,000	$29,224,000	$11,151,000
Operating Income	$-180,887,000	$-192,950,000	$-164,162,000	$-130,650,000
Per Share
Diluted EPS	$-1.94	$-2.00	$-1.63	$-1.39
Basic EPS	$-1.94	$-2.00	$-1.63	$-1.39
Other
Tax Effect Of Unusual Items	$0	$0	$0	$0
Tax Rate For Calcs	$0	$0	$0	$0
Normalized EBITDA (Bullshit earnings)	$-180,471,000	$-192,534,000	$-163,746,000	$-130,390,000
Reconciled Depreciation	$416,000	$416,000	$416,000	$260,000
EBITDA (Bullshit earnings)	$-180,471,000	$-192,534,000	$-163,746,000	$-130,390,000
EBIT	$-180,887,000	$-192,950,000	$-164,162,000	$-130,650,000
Diluted Average Shares	$81,495,352	$84,264,715	$83,389,750	$83,245,385
Basic Average Shares	$81,495,352	$84,264,715	$83,389,750	$83,245,385
Diluted NI Availto Com Stockholders	$-158,349,000	$-168,385,000	$-135,956,000	$-115,909,000
Tax Provision	$-6,162,000	$925,000	$1,018,000	$-3,590,000
Research And Development	$148,024,000	$144,101,000	$114,243,000	$81,936,000
Selling General And Administration	$32,863,000	$48,849,000	$49,919,000	$48,714,000
Other Gand A	$32,863,000	$48,849,000	$49,919,000	$48,714,000

Fetched: 2026-06-12

Balance Sheet (Annual)

Metric	2025-12-31	2024-12-31	2023-12-31	2022-12-31
Assets
Net Tangible Assets	$275,434,000	$438,867,000	$555,192,000	$640,572,000
Total Assets	$315,218,000	$464,668,000	$594,968,000	$666,708,000
Total Non Current Assets	$4,227,000	$2,313,000	$4,513,000	$5,786,000
Other Non Current Assets	$3,136,000	$197,000	$1,396,000	$1,692,000
Current Assets	$310,991,000	$462,355,000	$590,455,000	$660,922,000
Other Current Assets	$9,161,000	$7,634,000	$12,349,000	$14,213,000
Cash Cash Equivalents And Short Term Investments	$301,830,000	$454,721,000	$578,106,000	$646,709,000
Cash And Cash Equivalents	$95,713,000	$64,696,000	$143,823,000	$188,460,000
Non Current Prepaid Assets	-	-	-	$1,494,000
Prepaid Assets	-	-	-	-
Receivables	-	-	-	-
Debt
Total Debt	$843,000	$1,642,000	$2,402,000	$3,124,000
Long Term Debt And Capital Lease Obligation	$0	$842,000	$1,642,000	$2,403,000
Current Debt And Capital Lease Obligation	$843,000	$800,000	$760,000	$721,000
Liabilities
Total Liabilities Net Minority Interest	$39,784,000	$25,801,000	$39,776,000	$26,136,000
Total Non Current Liabilities Net Minority Interest	$0	$7,198,000	$7,400,000	$7,658,000
Tradeand Other Payables Non Current	$0	$6,356,000	$5,758,000	$5,255,000
Current Liabilities	$39,784,000	$18,603,000	$32,376,000	$18,478,000
Payables And Accrued Expenses	$38,941,000	$17,803,000	$31,616,000	$17,757,000
Payables	$12,945,000	$4,458,000	$4,252,000	$2,650,000
Accounts Payable	$12,945,000	$4,458,000	$4,252,000	$2,551,000
Total Tax Payable	-	-	$0	$99,000
Income Tax Payable	-	-	$0	$99,000
Other Non Current Liabilities	-	-	-	-
Current Deferred Liabilities	-	-	-	-
Equity
Common Stock Equity	$275,434,000	$438,867,000	$555,192,000	$640,572,000
Total Equity Gross Minority Interest	$275,434,000	$438,867,000	$555,192,000	$640,572,000
Stockholders Equity	$275,434,000	$438,867,000	$555,192,000	$640,572,000
Gains Losses Not Affecting Retained Earnings	$174,000	$233,000	$207,000	$-684,000
Other Equity Adjustments	$174,000	$233,000	$207,000	$-684,000
Retained Earnings	$-522,569,000	$-364,220,000	$-195,835,000	$-59,879,000
Other
Ordinary Shares Number	$78,126,796	$84,463,059	$83,435,513	$83,287,639
Share Issued	$78,126,796	$84,463,059	$83,435,513	$83,287,639
Tangible Book Value	$275,434,000	$438,867,000	$555,192,000	$640,572,000
Invested Capital	$275,434,000	$438,867,000	$555,192,000	$640,572,000
Working Capital	$271,207,000	$443,752,000	$558,079,000	$642,444,000
Capital Lease Obligations	$843,000	$1,642,000	$2,402,000	$3,124,000
Total Capitalization	$275,434,000	$438,867,000	$555,192,000	$640,572,000
Additional Paid In Capital	$797,751,000	$802,770,000	$750,737,000	$701,052,000
Capital Stock	$78,000	$84,000	$83,000	$83,000
Common Stock	$78,000	$84,000	$83,000	$83,000
Preferred Stock	$0	$0	$0	$0
Long Term Capital Lease Obligation	$0	$842,000	$1,642,000	$2,403,000
Current Capital Lease Obligation	$843,000	$800,000	$760,000	$721,000
Current Accrued Expenses	$25,996,000	$13,345,000	$27,364,000	$15,107,000
Net PPE	$1,091,000	$2,116,000	$3,117,000	$4,094,000
Accumulated Depreciation	$-1,521,000	$-1,105,000	$-689,000	$-273,000
Gross PPE	$2,612,000	$3,221,000	$3,806,000	$4,367,000
Leases	$1,475,000	$1,475,000	$1,475,000	$1,475,000
Other Properties	$639,000	$1,248,000	$1,833,000	$2,394,000
Machinery Furniture Equipment	$498,000	$498,000	$498,000	$498,000
Properties	$0	$0	$0	$0
Other Short Term Investments	$206,117,000	$390,025,000	$434,283,000	$458,249,000
Current Deferred Revenue	-	-	-	-

Fetched: 2026-06-12

Cash Flow Statement (Annual)

Metric	2025-12-31	2024-12-31	2023-12-31	2022-12-31
Free Cash Flow
Free Cash Flow	$-132,031,000	$-135,499,000	$-85,395,000	$-122,925,000
Operating Activities
Operating Cash Flow	$-132,031,000	$-135,499,000	$-85,395,000	$-120,982,000
Cash Flow From Continuing Operating Activities	$-132,031,000	$-135,499,000	$-85,395,000	$-120,982,000
Investing Activities
Investing Cash Flow	$188,793,000	$56,105,000	$40,303,000	$-455,410,000
Cash Flow From Continuing Investing Activities	$188,793,000	$56,105,000	$40,303,000	$-455,410,000
Capital Expenditure	-	-	-	$-1,943,000
Financing Activities
Repurchase Of Capital Stock	$-25,519,000	$0	-	-
Issuance Of Capital Stock	$58,000	$0	-	$230,000
Financing Cash Flow	$-25,745,000	$267,000	$257,000	$370,000
Cash Flow From Continuing Financing Activities	$-25,745,000	$267,000	$257,000	$370,000
Net Other Financing Charges	$-485,000	-	-	-
Net Common Stock Issuance	$-25,461,000	$0	-	$230,000
Common Stock Issuance	$58,000	$0	-	$230,000
Net Preferred Stock Issuance	-	-	-	$0
Preferred Stock Issuance	-	-	-	$0
Other
End Cash Position	$95,713,000	$64,696,000	$143,823,000	$188,658,000
Beginning Cash Position	$64,696,000	$143,823,000	$188,658,000	$764,680,000
Changes In Cash	$31,017,000	$-79,127,000	$-44,835,000	$-576,022,000
Proceeds From Stock Option Exercised	$201,000	$267,000	$257,000	$370,000
Common Stock Payments	$-25,519,000	$0	-	-
Net Investment Purchase And Sale	$188,793,000	$56,105,000	$40,303,000	$-453,467,000
Sale Of Investment	$470,732,000	$517,282,000	$602,665,000	$91,885,000
Purchase Of Investment	$-281,939,000	$-461,177,000	$-562,362,000	$-545,352,000
Change In Working Capital	$16,482,000	$-7,476,000	$16,163,000	$-46,586,000
Change In Other Current Liabilities	$-190,000	$-175,000	$-161,000	$765,000
Change In Other Current Assets	$-2,939,000	$0	$98,000	$-1,494,000
Change In Payables And Accrued Expense	$21,138,000	$-13,215,000	$14,362,000	$-39,606,000
Change In Accrued Expense	$12,651,000	$-13,421,000	$12,661,000	$-37,623,000
Change In Payable	$8,487,000	$206,000	$1,701,000	$-1,983,000
Change In Account Payable	$8,487,000	$206,000	$1,701,000	$-1,983,000
Change In Prepaid Assets	$-1,527,000	$5,914,000	$1,864,000	$-6,251,000
Stock Based Compensation	$20,720,000	$51,767,000	$49,428,000	$46,718,000
Amortization Of Securities	$-4,944,000	$-11,821,000	$-15,446,000	$-5,465,000
Deferred Tax	$-6,356,000	$0	-	-
Deferred Income Tax	$-6,356,000	$0	-	-
Depreciation Amortization Depletion	$416,000	$416,000	$416,000	$260,000
Depreciation And Amortization	$416,000	$416,000	$416,000	$260,000
Net Income From Continuing Operations	$-158,349,000	$-168,385,000	$-135,956,000	$-115,909,000
Net PPE Purchase And Sale	-	-	$0	$-1,943,000
Purchase Of PPE	-	-	$0	$-1,943,000
Change In Receivables	-	-	-	$0
Change In Other Working Capital	-	-	-	-

Fetched: 2026-06-12